Syndax’s axatilimab fails primary endpoint in pulmonary fibrosis trial
Syndax Pharmaceuticals (SNDX) reported that its Phase 2 trial of axatilimab for idiopathic pulmonary fibrosis did not meet the primary endpoint. The company will not pursue further development for this indication, but ongoing trials in chronic graft-versus-host disease will continue. Axatilimab was well-tolerated with no new safety concerns.
How this was made
The 30-second read
Why it matters
The negative Phase 2 result in idiopathic pulmonary fibrosis removes a potential near‑term revenue source, likely prompting a sell‑off.
Market read
The trial failure is a material event for SNDX and may influence peer biotech stocks with similar pipelines.
What to watch
The trial did not affect ongoing studies in other indications, which could mitigate the negative impact.
Background
Syndax Pharmaceuticals (NASDAQ:SNDX) is developing axatilimab, a CSF-1R‑blocking antibody, for multiple indications.
Ticker impact
Syndax announced its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis failed to meet the primary endpoint.
downward pressure as investors reassess the value of axatilimab after the negative data.
First disclosure of pivotal trial data for a biotech; such outcomes typically trigger immediate price moves.
Market effects
May dampen sentiment for fibrosis and broader biotech trial pipelines.
Limited to US-listed biotech investors.
Minimal beyond the biotech sector.
Counterpoint
Some investors may view the continued development in chronic graft-versus-host disease as a longer-term upside.
Key entities
- companySyndax Pharmaceuticals
Developer of axatilimab.
